{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "MAZE",
  "name": "Maze Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/MAZE/",
  "json_url": "https://orbyd.app/dossiers/MAZE.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "APOL1 kidney precision-medicine story with clinical proof-of-concept in hand (Mar-25 HORIZON: 35.6% proteinuria cut, 61.8% in FSGS), but the tape has rolled over — $27.68, down 26% YTD and ~48% off the 52-wk high, no hard binary until 2027, and a ~Aug-12 earnings blackout. Buy the base, don't chase the drift.",
  "invalidation_trigger": "A weekly close below $23.50 forfeits the April placement floor and the post-HORIZON base; a durability/eGFR miss in the additional HORIZON data (late-2026/early-2027), or a positive Vertex inaxaplin interim read that commoditizes the broad-AMKD edge, would confirm the structural break.",
  "catalyst_date": "2026-08-12",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Earnings blackout: Q2 2026 report est. ~mid-Aug 2026 — avoid fresh entries into an unconfirmed print date.",
    "Binary-catalyst biotech: size to catalyst risk, not beta. Thin float (~55.35M sh, light daily volume ~166k on Jul 24) — moves are gappy.",
    "Cash ~$528M (Q1 2026, Mar 31) + $144.7M April net; runway guided into 2029 — dilution is opportunistic, not distress.",
    "Key competitor = Vertex inaxaplin (VX-147) in Phase 3 AMPLITUDE; full enrollment guided H2 2026, interim data early 2027, possible U.S. accelerated-approval filing — bidirectional class cross-read.",
    "Next true value inflections = additional HORIZON durability/eGFR data (late-2026/early-2027) and MZE782 Phase 2 POC reads (PKU guided mid-2026, CKD H2 2026).",
    "ASN Kidney Week 2026 = Oct 21–25, Denver (corrects prior 2026-11-06 placeholder) — data-detail event, not a fresh binary.",
    "Earnings blackout: Q2 2026 report est. ~2026-08-12 (prior-year Q2 printed Aug 12, 2025) — avoid fresh entries into an unconfirmed print.",
    "Insider flag: CMO Harold Bernstein sold 14,609 sh @ $29.90 on 2026-07-01 (~$437k)."
  ],
  "body_markdown": "## Current Thesis\nMaze is a genetics-first, clinical-stage kidney biotech that owns real clinical proof-of-concept in APOL1-mediated kidney disease (AMKD) but whose tape has rolled over since the data ran. The March 25, 2026 Phase 2 HORIZON topline delivered the first efficacy signal in a *broad*, genetically-defined AMKD population — a 35.6% mean proteinuria (uACR) cut at week 12, 61.8% in the severe-FSGS subgroup — and the stock still trades at $27.68 (Jul 24, 2026; ~$1.53B cap), above the $23.50 April raise and roughly 70% over the $16 IPO (Jan 31, 2025). The problem for a fresh buyer is timing, not thesis: shares sit ~48% below the 52-week high of $53.65, are down 26.3% year-to-date despite a +14.1% one-month bounce, the next hard binary is a 2027 event, and a Q2 print (~Aug 12) opens an earnings blackout in roughly two weeks. This reads as a post-drawdown consolidation with no scheduled payoff, not an accelerating breakout — the base is worth accumulating, the drift is not worth chasing.\n\n## Bull Case\n- **First broad-AMKD proof-of-concept, Mar 25, 2026:** MZE829 (oral dual-mechanism APOL1 inhibitor) cut uACR 35.6% at week 12 across broad AMKD, with 50% of patients hitting >30% reduction — a signal in the genetically-defined population Maze intends to register, not just narrow high-proteinuria FSGS.\n- **Subgroup carries the value:** FSGS patients showed a 61.8% mean uACR reduction and non-diabetic AMKD 48.6% (Mar 25 topline) — the exact cohort slated for the planned H1 2027 pivotal.\n- **Clean tolerability, Mar 25:** no serious AEs and no severe treatment-related AEs across doses; most-frequent TRAEs were headache and diarrhea — a profile that supports chronic oral dosing.\n- **Second oral shot on goal, Sep 11, 2025:** MZE782 (SLC6A19 inhibitor) drove a 42-fold rise in urinary phenylalanine at 240mg BID across a 112-subject Phase 1, clearing it into two Phase 2 proof-of-concept reads (PKU guided mid-2026, CKD H2 2026).\n- **Funded through the pivotal:** ~$528M cash/marketable securities at Mar 31, 2026 (Q1 report May 12) plus $144.7M net from the April raise; runway guided into 2029, so dilution is opportunistic rather than forced.\n- **Sell-side still constructive:** Strong Buy consensus (12 analysts), average 12-month target ~$62.55 (~126% above $27.68), a high mark near $110 (Jun 22, 2026), Mizuho reaffirmed Buy Jun 23, 2026.\n\n## Bear Case\n- **Class leader is years ahead:** Vertex's inaxaplin (VX-147) is in the Phase 3 AMPLITUDE portion, full enrollment guided H2 2026 with interim data in early 2027 and a possible U.S. accelerated-approval filing. A positive Vertex read could commoditize the broad-AMKD differentiation before Maze starts its own pivotal.\n- **Insider is selling into strength:** CMO Harold Bernstein sold 14,609 shares at $29.90 on Jul 1, 2026 (~$437k) — a distribution flag near the top of the recent range, not accumulation.\n- **Surrogate, not outcome:** HORIZON is a 12-week uACR read; the additional HORIZON data due late-2026/early-2027 must show durability and eGFR/kidney-function support or the pivotal case softens to a proteinuria-only story.\n- **Dilution cadence is live:** the April 22–23 offering (5.54M shares + 0.85M pre-funded warrants at $23.50, ~$150M gross) landed weeks after the data and capped the tape; a multi-year burn invites repeat raises whenever the stock lifts.\n- **No near-term payoff, thin liquidity:** the next hard readout is a 2027 event, so months of theta and headline risk sit ahead against a ~55.35M-share float that trades gappy on light volume (166k shares Jul 24).\n- **Structure has broken down:** down 26.3% YTD and ~48% off the $53.65 52-week high; the one-year gain is now backward-looking, not forward momentum.\n\n## Setup & Price Structure\nAt $27.68 (Jul 24, 2026), MAZE sits inside a post-data consolidation: a July high of $33.50, a July low of $26.37, and the $23.50 April placement price beneath as the structural floor. The 52-week range is $12.81–$53.65, so price is mid-band and well off the highs, with a +14.1% one-month and +10.6% three-month bounce sitting inside a −26.3% year-to-date drawdown. Volume is thin (166k shares on Jul 24 vs a ~55.35M-share float), which makes moves gappy in both directions. The theme tag reads accelerating at the sector level, but this specific name's price action is maturing-to-consolidating — it is not printing new highs, and there is no cluster of APOL1 peers breaking out with it (the one true peer, Vertex, is a mega-cap on its own timeline). Fresh-entry quality here is a probe at best: the base near $26.37–$23.50 is where risk is defined, and a reclaim of $33.50 on expanding volume is what would flip the structure back to constructive.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-08-12 (est.):** Q2 2026 financial results and pipeline update — prior-year Q2 printed Aug 12, 2025. Expect a cash-runway/enrollment update rather than a binary; opens an earnings blackout, so fresh entries into an unconfirmed print carry gap risk.\n- **~mid/H2-2026 (est., no confirmed date):** MZE782 Phase 2 PKU proof-of-concept read was guided to mid-2026 — an unscheduled, potentially near-term data event; the CKD proof-of-concept read is guided H2 2026.\n- **Beyond 30 days, flagged:** ASN Kidney Week 2026 runs Oct 21–25 in Denver (corrects the prior 2026-11-06 placeholder), where Maze will present additional MZE829 and MZE782 detail — a data-detail event, not a fresh binary. The true value inflections remain the additional HORIZON durability/eGFR data (late-2026/early-2027) and the MZE782 Phase 2 reads.\n\n## What Would Change Our Mind\nThe constructive read breaks on a weekly close below $23.50, which forfeits the April placement floor and the post-HORIZON base and signals the offering-buyer bid has left. On fundamentals, a durability or eGFR miss in the additional HORIZON data (late-2026/early-2027) would demote the story to a proteinuria-only signal, and a positive Vertex inaxaplin interim read (early 2027) with kidney-function benefit would commoditize the broad-AMKD edge before Maze registers. On the upside, the setup re-rates if the MZE782 PKU proof-of-concept hits, ASN Kidney Week (Oct 21–25) adds durability detail, and price reclaims $33.50 on volume — that sequence turns the current drift back into an accelerating leg worth sizing into.\n\n## Correlation Notes\nThe dominant read-through is Vertex (VRTX): its inaxaplin program is the APOL1-class benchmark, and any AMPLITUDE efficacy or safety headline moves MAZE bidirectionally with no approved product to cushion a class stumble. Secondary adjacency runs to Travere (TVTX, sparsentan/FSGS) on the proteinuric-kidney read. As a pre-revenue, long-duration clinical-stage name, MAZE carries high beta to the XBI small-cap biotech tape and to rate direction — a risk-off or higher-yield regime pressures the whole cohort regardless of pipeline. The thin float amplifies all of it: index or basket flows move this ticker more than its fundamentals warrant on any given day.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T12:30:25+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}